Overview

Gout, a common form of inflammatory arthritis, is a considerable burden to patients and the health system. The rate of gout and hyperuricaemia in Australia is high relative to comparable countries and is increasing.1

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Describe the pathogenesis and the risk factors for developing gout
  • Discuss the current treatment recommendations for gout, including treat-to-target, and flare prophylaxis with urate-lowering therapy
  • Counsel on the safe and effective use of medicines used to treat gout, including adverse effects, hypersensitivity reactions and precautions.

Competency standards addressed (2016): 1.1, 1.6, 2.1, 2.4, 3.1, 3.2, 3.3 3.5

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.  

The prevalence of gout in older Australians is very high, affecting more than 2% of adults, and up to 10% of older males.2 The South Australian Health Omnibus Survey found the prevalence of gout was 6.5%.3 Gout prevalence in Australia is second only to New Zealand, which has the highest reported rate in the world.4 Prevalence increases with age in both men and women.2

Gout and hyperuricaemia are major health issues as they are associated with metabolic syndrome, diabetes mellitus, obesity and hypertension.5 Treatment with urate-lowering therapy has been shown to be beneficial in coronary heart disease, hypertension and chronic kidney disease.6

Observational studies suggest that gout is poorly managed in Australian primary care.2 A lifelong treatment strategy is required to prevent attacks and joint damage.

Clinical presentation

Gout is a chronic

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.